Compass Pathways reports Q2 EPS (41c) vs. (56c) last year

Cash and cash equivalents were $221.9M as of June 30, 2025 vs. $165.1M as of December 31, 2024. Cash position at June 30 is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2027. “With the recent positive 6-week primary endpoint from our first COMP360 Phase 3 study and the prior positive Phase 2b study, we have now delivered clinically meaningful and highly statistically significant top-line results after a single dose of COMP360 in two late-stage studies in treatment-resistant depression, a considerable achievement in psychiatry,” said Kabir Nath, Chief Executive Officer of Compass Pathways (CMPS). “As we look forward to the 006 data, our second phase 3 study, we are excited to see the efficacy of two fixed doses with the 6-week primary endpoint measurement only three weeks after the second dose. Given our recent positive phase 3 data, we are highly focused on solidifying our commercialization efforts and exploring pathways to get this potential paradigm changing treatment option to patients as quickly as possible.”